Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17039215 | 0.78 | GRM5 (0.54) | GRM5APLNROGAACACB | |
| SCHEMBL25066942 | 0.77 | PTK2 (0.33) | — | |
| SCHEMBL25067054 | 0.77 | KMT2A (0.38) | — | |
| SCHEMBL3348341 | 0.74 | GRM5 (0.51) | GRM5OGAACACB | |
| SCHEMBL22031532 | 0.74 | GRM5 (0.50) | GRM5OGA | |
| SCHEMBL17036514 | 0.73 | GRM5 (0.50) | GRM5OGAACACB | |
| SCHEMBL4788868 | 0.73 | — | — | |
| SCHEMBL14790425 | 0.72 | GRM5 (0.34) | GRM5 | |
| SCHEMBL739722 | 0.70 | GRM5 (0.47) | GRM5 | |
| SCHEMBL21536602 | 0.69 | GRM5 (0.46) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988502-B2 | Alpha-D-galactoside inhibitors of galectins | GALECTO BIOTECH AB (DK) | 2021-04-27 | — | — | US | disclosed |
| US-20190225638-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225638-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | LGALS1, LGALS2, LGALS3 | GRM5 1669/4885APLNR 659/4885OGA 297/4885 |
| US-10988502-B2 | Alpha-D-galactoside inhibitors of galectins | LGALS1, LGALS2, LGALS3 | GRM5 1669/4885APLNR 659/4885OGA 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.